News Sentiment

AKTS sentiment intelligence

Aktis Oncology, Inc. Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 24.89 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-10.7% over one week, +3.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -10.7% Price reacting lower
Trend fit Trend inactive 3.3% over four weeks
Fair value 19.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 48
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 9
Market source 9
simplywall.st 3
Moomoo 3
Investing.com Nigeria 3
GlobeNewswire 3
Bitget 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 16
Analyst action 5
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
TradingView Direct company coverage

Aktis Oncology Insiders Sold Shares Worth Over $2.8M

Two key officers at Aktis Oncology, Chief Medical Officer Czibere Akos and Chief Operating Officer Ron-Bigger Shulamit, sold significant amounts of common stock on July 8, 2026. Each officer sold shares totaling over $1.3 million, and following these transactions, neither directl

Tone
Negative 30/100
Event
Market update
Published
10 Jul 2026 10:19
Source
TradingView
Stock Titan Direct company coverage

Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares

Aktis Oncology's Chief Operating Officer, Shulamit Ron-Bigger, exercised 50,000 stock options at $3.66 per share and simultaneously sold 50,000 common shares in open-market transactions on July 8, 2026. The sales occurred at weighted average prices in the high-$20s per share. Fol

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 10:12
Source
Stock Titan
Stock Titan Direct company coverage

Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades

Aktis Oncology's Chief Medical Officer, Akos Czibere, executed an exercise-and-sell transaction on July 8, 2026. He exercised 50,000 stock options at $4.95 per share and subsequently sold all 50,000 acquired shares in multiple open-market transactions at weighted average prices i

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 10:12
Source
Stock Titan
Stock Titan Direct company coverage

Aktis Oncology, Inc. SEC Filing

Aktis Oncology, Inc. (AKTS) has filed a Form 144 with the SEC, indicating a proposed sale of 50,000 shares of common stock with an aggregate market value of $1,388,700. The securities were acquired on July 8, 2026, through an exercise of options under a registered plan, with paym

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:11
Source
Stock Titan
www.marketscreener.com Direct company coverage

Certain Options of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.

Aktis Oncology, Inc. has certain options subject to a lock-up agreement that ends on July 8, 2026. This agreement, which began on January 8, 2026, prevents company directors, executive officers, and major shareholders from selling or transferring common stock or convertible secur

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 23:10
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

34,872,279 Common Stock of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.

This article announces that 34,872,279 common stock shares of Aktis Oncology, Inc. are subject to a lock-up agreement, which began on January 8, 2026, and will end on July 8, 2026. This lock-up prevents company directors, executive officers, and substantial shareholders from sell

Tone
Negative 40/100
Event
Market update
Published
07 Jul 2026 20:23
Source
www.marketscreener.com
TradingView Direct company coverage

AKTS Forecast — Price Target — Prediction for 2027

Aktis Oncology, Inc. (AKTS) stock is currently trading at $29.44, having seen significant increases over the past week, month, and year. Analysts provide a price target range of $33.00 to $40.00, with a consensus of $35.50. The company's next earnings report is expected on Septem

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 06:10
Source
TradingView
Associated Press Direct company coverage

Aktis: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
11 May 2026 20:56
Source
Associated Press